Carteyva (Relmacabtagene Autoleucel Injection), an anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product has been approved for the treatment of adult patients with follicular lymphoma that is refractory or that relapses within 24 months of second-line or above systemic treatment (r/r FL).